Search Results 51-60 of 18676 for Parkinson's disease
Cytoplasmic deposition of alpha-synuclein aggregates is a common pathological feature of many neurodegenerative synucleinopathies, including Parkinson's ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Rodolfo Savica, M.D., Ph.D., studies biomarkers and risk factors to improve diagnosis and treatment of early-onset Parkinson's and related disorders.
This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline ...
Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders Lab investigates the link between alpha-synuclein, disease and major cellular ...
The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of ...
Researchers in this brain focus area of the Discovery and Translation Labs at Mayo Clinic study the molecular biology and genes that may drive Parkinson's ...
What is Parkinson's disease? This is a neurodegenerative condition that commonly occurs in people middle-aged and beyond. Sometimes, it occurs in younger people ...
The mitochondria are the cell's power plants, and many brain disorders, including Parkinson's, are characterized by disruption in energy production in neurons.
The Neurobiology of Parkinson's Disease Lab develops assays to study protein misfolding disorders. Molecular chaperone proteins are used by cells to promote ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift today can have 5X the impact on AI research and technology. But hurry — the match challenge ends 9/19.